Names and pronunciation
(free-ma-nez′ue-mab) Ajovy
PDF page 606
Loading InternPractice…
Drug reference
(free-ma-nez′ue-mab) Ajovy
PDF page 606
Func. class.: Antimigraine agent
PDF page 606
Chem. class.: Calcitonin gene-related peptide (CGRP) antagonist
PDF page 606
ACTION: Binds to and antagonizes the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function
PDF page 606
USES: Migraine prophylaxis
PDF page 606
CONTRAINDICATIONS: Hyper sensitivity Precautions: Breastfeeding, pregnancy
PDF page 606
SIDE EFFECTS INTEG: Injection site reaction, rash, urti- caria, pruritus, erythema MISC: Antibody formation
PDF page 607
INTERACTIONS None known
PDF page 607
DOSAGE AND ROUTES • Adult: SUBCUT 225 mg monthly or 675 mg q3mo
PDF page 606
Available forms: 225 mg/1.5 mL pre- filled syringe sol for injection
PDF page 606
Administer: SUBCUT route • When switching between monthly and quarterly dosage options, give the first dose of the new regimen on the next scheduled date of administration • Visually inspect for particulates, dis- coloration before use; do not use if solu- tion is cloudy, discolored, or contains particles; product is clear to opalescent, colorless to slightly yellow • Allow to sit at room temperature ≥30 min, protect from direct sunlight, do not shake • Clean injection site on the abdomen, thigh, or upper arm with an alcohol wipe, and allow skin to dry • Do not inject into areas where skin is tender, bruised, red, or hard. Avoid injecting directly into raised, thick, red, or scaly skin patch or lesion, or into areas with scars or stretch marks • If using the same body area for the 3 separate injections needed for the 675-mg dose, do not use the same loca- tion used for the previous injection • Do not coadminister with other injectable drugs at the same injection site • If a dose is missed, give the next dose as soon as possible • Storage: After removing from refrig- erator, may be stored at room tempera- ture up to 77° F (25° C) for ≤24 hr; discard if not used within 24 hr after removal from refrigerator Single-dose prefilled syringe • Pinch injection site skin firmly between thumb and fingers • Hold, insert syringe at a 45- to 90-degree angle for administration
PDF pages 606, 607
Assess: • Migraine: pain, location, intensity, duration, photophobia in the past; assess response to preventing migraine after use of this product • Injection site reaction, rash, urticaria, pruritus, erythema; may indicate allergic reactions • Pregnancy/breastfeeding: identify if pregnancy is planned or suspected, or if breastfeeding; no adequate studies are available
PDF page 607
Evaluate: • Therapeutic response: prevention of migraine
PDF page 607
CLINICAL CONSIDERATIONS
PDF page 607
Patient and caregiver information: • How to self-administer product • Not to double, skip doses; when switching between monthly and quarterly dosage options, to give the first dose of the new regimen on the next scheduled date of administration • To report injection site reaction, rash, itching; may indicate allergic reaction
PDF page 607
PHARMACOKINETICS Half-life 31 days, peak 5-7 days
PDF page 607
• Adult: SUBCUT 225 mg monthly or 675 mg q3mo
PDF page 606